Portal de Periódicos da CAPES

Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

1996; Elsevier BV; Volume: 100; Issue: 4 Linguagem: Inglês

10.1016/s0002-9343(97)89522-8

1555-7162

Jorge E. Cortés, Hagop M. Kantarjian, Susan O’Brien, L. E. Robertson, Sherry Pierce, Moshe Talpaz,

Acute Myeloid Leukemia Research

Purpose To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. Patients and methods Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5 × 106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. Results Thirty-five of 274 (13%) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51% had a cytogenetic response, which was major in 26% and complete (Philadelphia chromosome-positive cells = 0%) in 20%. Their median survival was 64 months, and the estimated 5-year survival rate was 62%. These results were not different from those in younger patients. Twenty-two patients (63%) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31% and chronic fatigue in 29%. Conclusions Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management. To determine the response rate to interferon-alpha (IFN-α) in patients with chronic myelogenous leukemia (CML) aged 60 years and older. Patients with CML aged 60 years and older included in all protocols with IFN-α therapy for early chronic phase CML at the M.D. Anderson Cancer Center were analyzed. They were treated with human leukocyte or recombinant human IFN-α 5 × 106 U/m2 daily alone or in combination with hydroxyurea or IFN gamma. The clinical characteristics of the patients were analyzed and their hematologic and cytogenetic responses to IFN-α and survival from the initiation of therapy were determined. Results were compared with those of younger patients treated in the same protocols. Treatment-related toxicity was also analyzed. Thirty-five of 274 (13%) patients included in trials of IFN-α-based regimens for CML were 60 years and older. Older patients had a higher percentage of bone marrow blasts (P = 0.04) and basophils (P = 0.09) than younger patients. Sixty-nine percent achieved a complete hematologic remission with IFN-α therapy, and 51% had a cytogenetic response, which was major in 26% and complete (Philadelphia chromosome-positive cells = 0%) in 20%. Their median survival was 64 months, and the estimated 5-year survival rate was 62%. These results were not different from those in younger patients. Twenty-two patients (63%) had at least grade 2 toxicity requiring dose adjustment. The most frequent side effects were neurotoxicity in 31% and chronic fatigue in 29%. Patients with CML 60 years of age and older respond well to IFN-α therapy, but experience more toxicity. This therapy should be considered for these patients if they are otherwise in good condition, with careful attention to IFN-α toxicity and its management.